Hormonal
Tirzepatide produces the greatest weight loss and superior cardiometabolic improvements (blood pressure, triglycerides, glucose) among FDA/EMA-approved anti-obesity medications.
If you have obesity and comorbidities, Tirzepatide is currently the most effective FDA-approved medication for weight loss and improving metabolic markers like blood pressure and blood sugar. It outperforms Semaglutide in weight reduction magnitude.
Tirzepatide had the greatest weight-loss effect (WMD −11.69... moderate certainty)... Tirzepatide had the strongest antihypertensive effect... and best reduced triglycerides... fasting glucose... insulin... and glycated haemoglobin levels... Tirzepatide emerges as the optimal choice for weight loss in clinical practice.
Why this rating
Based on 154 RCTs with moderate to high certainty ratings for most outcomes.
Source
Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis
Leiling Liu et al. · EClinicalMedicine · 2024
DOI 10.1016/j.eclinm.2024.103020
More from this paper
- Semaglutide and Liraglutide reduce the risk of Major Adverse Cardiovascular Events (MACEs), whereas Naltrexone/Bupropion increases the risk of elevated blood pressure.Good
- Phentermine/Topiramate increases the risk of psychological side effects including depression, anxiety, sleep disorders, and irritability.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →